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Abstract
Candida parapsilosis former groups II and III have recently been established as independent species, named Candida orthopsilosis and Can-
dida metapsilosis, respectively. We investigated the distribution of C. parapsilosis complex species in 122 isolates from blood and other
sources in a southern Spain tertiary-care hospital, and we examined the relationship between species, site of isolation and bioﬁlm posi-
tivity. We also evaluated the planktonic MICs and sessile MICs (SMICs) of voriconazole, amphotericin B and anidulafungin. One hundred
and eleven isolates (91%) were categorized as C. parapsilosis sensu stricto, whereas ten isolates (8.2%) were categorized as C. orthopsilo-
sis and one (0.8%) as C. metapsilosis. Bioﬁlm positivity was observed in 58.5% (65 of 111) of C. parapsilosis sensu stricto isolates vs. 0%
(0 of 11) of C. orthopsilosis and C. metapsilosis isolates (p <0.01). There was no difference in bioﬁlm production among C. parapsilosis sen-
su stricto isolates from blood and other sources. MIC values showed that all isolates were susceptible to voriconazole and amphoteri-
cin B, whereas two isolates (1.8%) of C. parapsilosis sensu stricto were non-susceptible to anidulafungin. However, the MIC90 value of
voriconazole was higher (0.125 mg/L) for C. orthopsilosis than forC. parapsilosis sensu stricto (0.03 mg/L). In contrast to planktonic cells,
the SMICs show that amphotericin B and anidulafungin are moderately effective against the bioﬁlm of C. parapsilosis sensu stricto,
whereas voriconazole is ineffective.
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Introduction
Candida parapsilosis is well known as a cause of nosocomial
bloodstream infections, particularly among neonates and
immunocompromised patients, and it is associated with candi-
daemia caused by intravascular devices and parenteral nutri-
tion [1–3,7,16,24]. Traditionally, C. parapsilosis was separated
into three groups, I–III [4]. However, Tavanti et al. [5] recently
proposed the separation of the groups into closely related, dis-
tinct species, C. parapsilosis sensu stricto, Candida orthopsilosis
and Candida metapsilosis, to replace groups II and III. As com-
mercially available assays are not able to differentiate groups,
DNA-based techniques are needed, and few published studies
have made this discrimination [19,27]. In order to distinguish
between the three species, Tavanti et al. [6] proposed the
analysis of restriction polymorphism of the secondary alcohol
dehydrogenase (SADH) gene, which encodes a secondary
alcohol dehydrogenase and is common to all three species.
Although strains from each species are found in samples
from human patients, clinical isolates are predominantly
C. parapsilosis sensu stricto [8]. Patients requiring prolonged
use of central venous catheters and parenteral nutrition are
at high risk for invasive disease, probably because of the
ability of C. parapsilosis to form bioﬁlms on the surface of
indwelling devices and prosthetic materials [9,11,13]. This
bioﬁlm can also confer resistance to antifungal therapy and
protect the yeast cells from host immune responses.
There are few publications describing the antifungal sus-
ceptibility proﬁles of the new species C. orthopsilosis and
C. metapsilosis. These scant data suggest that C. orthopsilosis
and C. metapsilosis could be more susceptible to amphoteri-
cin B and echinocandins than C. parapsilosis [8,14,15,25].
This fact would have clinical relevance, as it may inﬂuence
therapeutic decisions.
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In order to determine the clinical importance of C. par-
apsilosis in our area, we decided to describe the occurrence
of the new species C. orthopsilosis and C. metapsilosis in the
population attending at our hospital. Furthermore, we inves-
tigated their ability to form bioﬁlm, to establish the relation-
ship between species and the site of isolation with bioﬁlm
production. Finally, we also compared planktonic MICs and
sessile MIC (SMICs) of voriconazole, amphotericin B and ani-
dulafungin for clinical C. parapsilosis complex.
Materials and Methods
One hundred and twenty-two C. parapsilosis complex strains
were collected from patients admitted to different units of
Virgen del Rocı´o Hospital. C. parapsilosis complex strains
were isolated from different clinical specimens, including
blood, catheter tip, oropharyngeal, vaginal, urine, skin and
nail specimens. Only one isolate per patient was included in
this study. They were selected from strains previously identi-
ﬁed and maintained at )70C. For species identiﬁcation, the
strains were plated into CHROMagar Candida (CHROMagar
Microbiology, Paris, France) to check the purity and viability
of all original yeast cultures. All isolates were identiﬁed by
biochemical tests performed with the commercial ID32C
system (BioMerieux, Marcy l’Etoile, France).
Bloodstream isolates were deﬁned as the isolates obtained
from the semiquantitative catheter tip culture, which yielded
more than 15 CFU of C. parapsilosis complex, as well as iso-
lates from blood. The isolates of the remaining samples were
classiﬁed as ‘other location group’.
DNA isolation and ampliﬁcation
Isolates were stored in sterile 20% glycerol, passaged on Sab-
ouraud agar, and then plated fresh on Sabouraud agar and
incubated at 30C for 24 h. Yeast genomic DNA was
extracted with a MasterPure Yeast Puriﬁcation kit (Epicentre,
Madison, WI, USA), according to the manufacturer’s instruc-
tions.
Randomly ampliﬁed polymorphic DNA (RAPD) PCR
C. parapsilosis isolates were screened by the RAPD technique
with the primer RPO2 (5¢-GCGATCCCCA-3¢) [5]. Reaction
volumes of 50 lL contained 100 ng of genomic DNA, 1.5 U
of Taq polymerase (Promega, Madison, WI, USA), 5 lL of
10· magnesium-free buffer, 3 lL of 25 mM MgCl2, 200 lM
deoxynucleoside triphosphates, and 10 lM primer. The DNA
products were ampliﬁed with a ﬁrst cycle of denaturation for
2 min at 94C, followed by 35 cycles of denaturation at 94C
for 1 min, annealing at 36C for 1 min, and elongation at
72C for 75 s, with a ﬁnal extension step of 10 min at 72C.
Ampliﬁed DNA products were separated by electrophoresis
in a 1% agarose gel containing ethidium bromide.
BanI digestion of SADH fragment
Primers S1F and S1R, which amplify the SADH gene, were
used for the PCR [5]. Following completion of the cycle, 1 lL
of BanI (New England Biolabs, Ipswich, MA, USA) was added
directly to the reaction mixture, and the mixture was incu-
bated for 2 h at 37C. Isolates of C. parapsilosis, C. orthopsilosis
and C. metapsilosis were identiﬁed by the size of the major
restriction fragment on an agarose gel following digestion. All
isolates identiﬁed as C. orthopsilosis and C. metapsilosis were
ampliﬁed and digested a second time for conﬁrmation. ATCC
isolates 96139 and 96144 were used as positive controls for
C. orthopsilosis and C. metapsilosis, respectively.
Bioﬁlm formation
All experiments were performed in presterilized, polystyrene,
ﬂat-bottomed, 96-well microtitre plates. Standardized cell sus-
pensions (100-lL portions of suspensions containing
1.0 · 103 cells/mL in RPMI-1640) were seeded into selected
wells of the microtitre plates and incubated for 48 h at 37C.
Following the initial incubation, the medium was aspirated,
and non-adherent cells were removed by thoroughly washing
the preparations three times with sterile phosphate-buffered
saline. Brieﬂy, a mixture (100 lL) of 2,3-bis(2-methoxy-4-
nitro-5-sulpho-phenyl)-2H-tetrazolium-5-carboxanilide (XTT)
(0.5 mg/mL in Ringer’s lactate) and menadione (10 mM, pre-
pared in acetone; Sigma Chemical Co.), added to a ﬁnal con-
centration of 1 lM acetone, was placed into each well [12,
17]. The plates were then incubated in the dark for 1 h at
37C, and the colorimetric change at 492 nm (a reﬂection of
the metabolic activity of the bioﬁlm) was measured with a
microtitre plate reader. The experiments were performed
with three replicates for each strain, three times each. The
bioﬁlm production was measured as optical densities higher
than >0.200. The absorbance values of the negative control
wells (containing no cells) were subtracted from the values of
the test wells.
Antifungal agents
Standard antifungal powders of voriconazole (Pﬁzer, Groton,
CT, USA), amphotericin B (Sigma, St Louis, MO, USA) and
anidulafungin (Pﬁzer) were obtained from the respective
manufacturers. Stock solutions of voriconazole, amphoteri-
cin B and anidulafungin were prepared in dimethylsulphoxide
(Sigma). Antifungal agents were then diluted with RPMI-1640
medium (Sigma) and buffered to pH 7.0 with morpholine-
propranesulphonic acid buffer (Sigma).
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Antifungal agent susceptibility testing
The MICs for planktonic cells were determined according to
the standard CLSI document M27-A3 [18]. Voriconazole,
amphotericin B and anidulafungin concentrations ranged from
0.03 to 16 mg/L. CLSI breakpoints for susceptibility were
used for voriconazole and anidulafungin, and a provisional sus-
ceptible breakpoint of £1 mg/L was used for amphotericin B.
The MICs for sessile cells (bioﬁlms) were determined with
the previously described microtitre assay [17]. Mature bioﬁlms
were allowed to form in 96-well microtitre plates for 48 h,
and the cell densities of the bioﬁlms were estimated using the
XTT absorbance assay. The antifungal agents were prepared
in a series of two-fold dilutions from 16 to 0.03 mg/L.
The inhibitory effects of the antifungals were measured as
the optical densities of the antifungal-treated wells relative to
those of the control (antifungal-free) wells (considered to be
100%), as determined in the XTT assays, and are expressed
as percentages (MIC50 and MIC80) of the values for control
wells. All isolates were tested at least twice.
Statistical analyses
The chi-square test was used to compare bioﬁlm positivity
between C. parapsilosis sensu stricto isolates recovered from
blood cultures and those recovered from different sources
and between different species. Differences between groups
were considered to be signiﬁcant when the p-value was <0.05.
Results
Species identiﬁcation of C. parapsilosis complex
All of the isolates were screened by RAPD testing, with the
primer RPO2, and low-stringency conditions to amplify geno-
mic DNA (Fig. 1).
For C. parapsilosis complex, a fragment of the SADH gene
(716 bp) was ampliﬁed by PCR. According to the BanI
restriction pattern of the above fragment, isolates were
molecularly discriminated as C. parapsilosis sensu stricto,
C. orthopsilosis and C. metapsilosis (Fig. 2). C. parapsilosis sen-
su stricto has one BanI restriction site, at position 196,
C. orthopsilosis has none and C. metapsilosis has three (posi-
tions 96, 469 and 529). The distribution of the three species
is presented in Table 1.
Bioﬁlm production of C. parapsilosis complex
A total of 65 (53.2%) of the 122 C. parapsilosis complex
isolates were bioﬁlm-positive (Table 2). C. parapsilosis sensu
stricto was the only species that was able to produce
bioﬁlms (65 of 111 strains), whereas none of the ten clinical
isolates of C. orthopsilosis nor the only one strain of
C. metapsilosis was found to produce bioﬁlm in vitro.
Bloodstream isolates of C. parapsilosis sensu stricto were
not signiﬁcantly (p >0.05) more likely to be bioﬁlm-positive
than C. parapsilosis sensu stricto isolates from other sites
(65% (39 of 60) vs. 50.9% (26 of 51)).
Antifungal susceptibility proﬁle
MICs for planktonic cells. Antifungal susceptibility testing results
for voriconazole, amphotericin B and anidulafungin, including
MIC ranges, MIC50s and MIC90s, are summarized in Table 3.
All isolates were susceptible to voriconazole and ampho-
tericin B, and two (1.8%) C. parapsilosis sensu stricto isolates
were non-susceptible to anidulafungin. The overall activities
of voriconazole, amphotericin B and anidulafungin were simi-
lar for the three species: most of the isolates were inhibited
by <0.125 mg/L voriconazole, 1 mg/L amphotericin B and
2 mg/L anidulafungin. However, the voriconazole MIC90 was
higher (0.125 mg/L) for C. orthopsilosis than for C. parapsilosis
sensu stricto (0.03 mg/L).
MICs for sessile cells. We evaluated the activities of amphoter-
icin B, voriconazole and anidulafungin against sessile (bioﬁlm)
forms of the 59 bioﬁlm-positive C. parapsilosis sensu stricto
isolates.
The distribution of antifungal MICs for planktonic (MIC)
and sessile (SMIC) cells of C. parapsilosis sensu stricto are
shown in Table 4.
The anidulafungin SMIC50s and SMIC80s for sessile cells
(bioﬁlms) ranged from 0.03 to 16 mg/L and from 0.5 to
>16 mg/L, and the median anidulafungin SMIC50s and
MM654321 7 8 9 10 11 12 13 14 15 16 17 18
FIG. 1. Randomly ampliﬁed polymorphic DNA (RAPD) patterns produced for Candida parapsilosis strains with the primer RPO2. Lanes 1, 5, 6,
8, 9 and 11–18: representative RAPD proﬁles for C. parapsilosis group I. Lanes 2–4 and 10: group II. Lane 7: group III.
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SMIC80s were 2 and 4 mg/L, respectively. The voriconazole
SMIC50s and SMIC80s ranged from 0.03 to >16 mg/L and
from 2 to >16 mg/L, and the median SMIC50s and SMIC80s
were 8 and >16 mg/L, respectively. The amphotericin B
SMIC50s and SMIC80s ranged from 0.03 to 0.5 mg/L and from
0.125 to 2 mg/L, and the median SMIC50s and SMIC80s were
0.125 and 0.5 mg/L, respectively.
These data show that amphotericin B and anidulafungin
are moderately effective against the bioﬁlm of C. parapsilosis
sensu stricto, whereas voriconazole is ineffective.
Fig. 3 shows the inhibition curves for bioﬁlm-producing
C. parapsilosis sensu stricto isolates in the presence of differ-
ent concentrations of the three antifungal agents.
Discussion
C. parapsilosis is a yeast species that is isolated most fre-
quently from the skin, especially from the subungual space of
healthy people [11], and it is considered to be a part of the
normal microﬂora. On the other hand, it has become an
important nosocomial pathogen that causes serious diseases,
particularly bloodstream infections and endocarditis.
The interest in better characterization of the ‘psilosis’
group arises from the epidemiology of C. parapsilosis infec-
tions, which are now considered to be the second most fre-
quent type of bloodstream infection caused by yeast in
Europe, Canada and Latin America [1,15].
In this article, we report the species distribution, bioﬁlm
formation and antifungal susceptibility of a collection of 122
C. parapsilosis complex isolates from a southern Spain ter-
tiary-care hospital.
After molecular identiﬁcation of a large set of C. parapsilo-
sis isolates from a university hospital, 91% were found to be
C. parapsilosis sensu stricto, and 8.2% and 0.8% corresponded
to C. orthopsilosis and C. metapsilosis, respectively. The species
distribution found in our study agrees with data reported by
international studies [10,28].
We found that six of ten C. orthopsilosis isolates were
recovered from blood, and these results suggest that C. ort-
hopsilosis, as well as being a normal human commensal, could
also be a human pathogen. On the other hand, only one
C. metapsilosis isolate was obtained from a skin sample. Inter-
estingly, C. metapsilosis has been reported to be rarely recov-
ered from clinical samples [6].
Bioﬁlm formation is a virulence factor for C. parapsilosis
complex, as it confers signiﬁcant resistance to antifungal
therapy by limiting the penetration of substances through the
matrix and protecting the cell from host immune responses
[20].
With regard to the relationship between species and bio-
ﬁlm positivity, 58.5% of C. parapsilosis sensu stricto isolates
were bioﬁlm-positive, whereas none of the clinical isolates of
C. orthopsilosis and C. metapsilosis were found to produce bio-
ﬁlm in vitro. This ﬁnding agrees with the results of previous
studies by Song et al. [21] and Tavanti et al. [6], which have
been the only ones to determine bioﬁlm production at the
species level. This study has shown that bioﬁlm production
differs among the three species, and that a majority of
the isolates from the bloodstream and other sources are
C. parapsilosis sensu stricto, which has the ability to produce
bioﬁlm.
Some authors have studied the difference in bioﬁlm
positivity between the blood and other body site isolates, to
1 2 3 4 5 6 M 7 8 9 10 11
FIG. 2. BanI restriction digestion of secondary alcohol dehydroge-
nase (SADH) PCR products obtained from representative Candida
metapsilosis (lane 10), Candida orthopsilosis (lane 9) and Candida par-
apsilosis (lanes 1–8 and 11) strain types. Lane M: 100-bp ladder.
TABLE 1. Distribution of Candida parapsilosis, Candida ort-
hopsilosis and Candida metapsilosis
Site of isolation
No. of C.
parapsilosis
sensu stricto
isolates
No. of C.
orthopsilosis
isolates
No. of C.
metapsilosis
isolates
Total
no. of
isolates
Biopsy 3 0 0 3
Bloodstream 56 6 0 62
Central venous catheter 3 0 0 3
Hospital environmental 1 0 0 1
Mucosal surface 9 0 0 9
Otic 16 3 0 19
Respiratory tract 2 0 0 2
Skin 18 0 1 19
Synovial ﬂuid 1 0 0 1
Urine 1 1 0 2
Valvular spinal ﬂuid 1 0 0 1
Total 111 (91%) 10 (8.2%) 1 (0.8%) 122
TABLE 2. Comparison of bioﬁlm production by Candida
parapsilosis complex obtained from sites of invasion and
from other sources
No. of bioﬁlm-positive/total no. (%)
C. parapsilosis species (no.) Bloodstream Other sources Total
C. parapsilosis sensu stricto (111) 39/60 (65) 26/51 (50.9) 65/111 (58.5)
Candida orthopsilosis (10) 0/6 (0) 0/4 (0) 0/10 (0)
Candida metapsilosis (1) – 0/1 (0) 0/1 (0)
Total C. parapsilosis complex (122) 39/66 (59.1) 26/56 (46.42) 65/122 (53.2)
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determine whether bioﬁlm formation plays an important role
in the development of bloodstream infections [20,21,22,23,26].
In our study, we found C. parapsilosis sensu stricto bioﬁlm
production in 65% of bloodstream isolates and in 50.9% of
isolates from other sites. Hence, we found no signiﬁcant
differences in bioﬁlm formation among isolates recovered
from blood and isolates from other sites.
Our results agree with the ﬁndings of Song et al. [21] and
Branchini et al. [22], who did not ﬁnd differences between the
bloodstream and other sites. In contrast to our ﬁndings, Shin
et al. [26] reported that 86% of bloodstream isolates were
capable of forming bioﬁlm, as compared with 47% of isolates
from other sites. Ruzicka et al. [23] found that 59% of blood-
stream isolates produced bioﬁlm, vs. 39% of skin isolates, but
pointed out that only 32 blood isolates were studied.
Finally, we also compared planktonic MIC and SMIC values
for clinical isolates of C. parapsilosis complex of voriconazole,
amphotericin B and anidulafungin.
Planktonic MIC values showed that all isolates of C. par-
apsilosis complex were susceptible to three antifungal agents.
The susceptibility proﬁles for voriconazole, amphotericin B
and anidulafungin of C. parapsilosis complex isolates from our
hospital are similar to those described in other surveys [10,
28].
There have been few reports of the antifungal suscepti-
bility proﬁles of the three species since they were formally
separated, but these previous studies have shown concor-
dant results, indicating that both C. orthopsilosis and C. me-
tapsilosis have amphotericin B and echinocandins MICs
lower than those of C. parapsilosis [2,14,23,29]. Although
they have slightly higher ﬂuconazole MICs overall than
C. parapsilosis, all of the C. metapsilosis and C. orthopsilosis
isolates were susceptible to ﬂuconazole. Indeed, all of the
results suggest that the slight differences in antifungal sus-
ceptibility shown by the three Candida species that we
tested suggest that routine discrimination among C. parapsi-
losis complex species is not necessary for the clinical
laboratory.
Valid statistical comparison among the three species,
regarding the antifungal susceptibility pattern, is precluded
because of the low number of tested strains of C. orthopsilosis
and C. metapsilosis.
Our results regarding SMICs for 59 C. parapsilosis sensu
stricto bioﬁlm-producing isolates are in accordance with
TABLE 3. Antifungal planktonic susceptibilities of Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsi-
losis to the voriconazole, amphotericin B and anidulafungin
Species (no of isolates) Antifungal MIC (mg/L) range MIC50 (mg/L) MIC90 (mg/L) % Susceptible
C. parapsilosis (n = 111) VRC <0.03–0.125 <0.03 0.03 100
AMB 0.125–1 1 1 100
ANI 0.5–4 2 2 98.2
C. orthopsilosis (n = 10) VRC 0.03–0.5 0.06 0.125 100
AMB 0.25–1 0.5 1 100
ANI 0.5–2 1 1 100
C. metapsilosis (n = 1) VRC 0.06 – – –
AMB 0.5 – – –
ANI 1 – – –
VRC, voriconazole; AMB, amphotericin B; ANI, anidulafungin; MIC50, the MIC at which 50% of strains are inhibited; MIC90, the MIC at which 90% of strains are inhibited.
TABLE 4. Distribution of antifungal MICs for planktonic and sessile cells of Candida parapsilosis sensu stricto bioﬁlm producers
Antifungal Type of MIC
No. of isolates with MIC (mg/L) of:
<0.03 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 >16
Anidulafungin MIC 1 14 44
SMIC50 1 1 1 1 7 12 10 12 8 6
SMIC80 3 5 13 8 17 6 7
Amphotericin B MIC 1 24 34
SMIC50 10 6 22 10 11
SMIC80 13 5 15 12 14
Voriconazole MIC 36 19 4
SMIC50 1 1 2 4 5 14 14 5 13
SMIC80 1 2 5 6 45
SMIC50s and SMIC80s (MICs for sessile forms (bioﬁlms)) were determined by measuring 2,3-bis(2-methoxy-4-nitro-5-sulpho-phenyl)-2H-tetrazolium-5-carboxanilide activity
reduction.
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previously published data [30], showing that amphotericin B
and anidulafungin are moderately effective against the
C. parapsilosis bioﬁlms, whereas voriconazole is ineffective;
however, even at the highest concentrations of the three
drugs tested, the complete killing of bioﬁlms was never
achieved.
Antifungal susceptibility studies of the clinical isolates have
demonstrated a rise in the planktonic MIC in relation to the
corresponding SMIC. It can be argued that in the case of the
‘psilosis’ complex, it could be more relevant to determine
whether the strain is a bioﬁlm producer than to determine
what species it belongs to.
However, surveillance is needed to monitor changes in
the species distribution and antifungal susceptibility within
this species complex.
Transparency Declaration
The authors declare no conﬂict of interest with respect to
this article.
References
1. Almirante BJ, Alonso-Tarres L, Rodriguez-Tudela JL, Pahissa A. Epide-
miology, risk factors and prognosis of Candida parapsilosis blood-
stream infections: case-control population-based surveillance study of
patients in Barcelona, from 2002 to 2003. J Clin Microbiol 2006; 44:
1681–1685.
2. Girmenia CP, Martino F, De Bernardis F et al. Rising incidence of
Candida parapsilosis fungemia in patients with hematologic malignan-
cies: clinical aspects, predisposing factors and differential pathogenic-
ity of the causative strains. Clin Infect Dis 1996; 23: 506–514.
3. Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia:
trends in species distribution and antifungal susceptibility. J Clin Micro-
biol 2002; 40: 3551–3557.
4. Roy B, Meyer SA. Conﬁrmation of the distinct genotype groups
within the form species Candida parapsilosis. J Clin Microbiol 1998; 36:
216–218.
5. Tavanti A, Davison AD, Grow NAR, Maiden MCJ, Odds FC. Candida
orthopsilosis and Candida metapsilosis spp. nov. to replace Candida par-
apsilosis groups II and III. J Clin Microbiol 2004; 43: 284–292.
6. Tavanti A, Hensgens LAM, Ghelardi E, Campa M, Senesi S. Genotyp-
ing of Candida orthopsilosis clinical isolates by ampliﬁcation fragment
length polymorphism reveals genetic diversity among independent
isolates and strain maintenance within patients. J Clin Microbiol 2007;
45: 1455–1462.
7. Trofa D, Ga´cser A, Nosanchuk JD. Candida parapsilosis, an emerging
fungal pathogen. Clin Microbiol Rev 2008; 21: 606–625.
8. Go´mez-Lo´pez A, Alastruey-Izquierdo A, Rodrı´guez D et al. Preva-
lence and susceptibility of Candida metapsilosis and Candida orthopsilo-
sis: results from population-based surveillance of candidemia in Spain.
Antimicrob Agents Chemother 2008; 52: 1506–1509.
9. Kuhn DM, Mukherjee PK, Clark TA et al. Candida parapsilosis character-
ization in an outbreak setting. Emerg Infect Dis 2004; 10: 1074–1081.
10. Lockhart SR, Messer SA, Pfaller MA, Diekema DJ. Geographic distri-
bution and antifungal susceptibility of the newly described species
Candida orthopsilosis and Candida metapsilosis, in comparison to the
closely-related species Candida parapsilosis. J Clin Microbiol 2008; 46:
2659–2664.
11. McGinley KJ, Larson EL, Leyden JJ. Composition and density of
microﬂora in the subungual space of the hand. J Clin Microbiol 1988;
26: 950–953.
12. Pfaller MA, Barry AL. Evaluation of a novel colorimetric broth micro-
dilution method for antifungal susceptibility testing of yeast isolates.
J Clin Microbiol 1994; 32: 1992–1996.
13. Pfaller MA, Messer SA, Hollis RJ. Variation in DNA subtype, antifun-
gal susceptibility, and slime production among clinical isolates of Can-
dida parapsilosis. Diagn Microbiol Infect Dis 1995; 21: 9–14.
14. Asbeck E, Clemons KV, Martinez M, Tong A, Stevens DA. Signiﬁcant
differences in drug susceptibility among species in the Candida parapsi-
losis group. Diagn Microbiol Infect Dis 2008; 62: 106–109.
15. Pfaller MA, Diekema DJ, Gibbs DL et al. Geographic and temporal
trends in isolation and antifungal susceptibility of Candida para-
psilosis: a global assessment from the ARTEMIS DISK Antifungal
Surveillance Program, 2001 to 2005. J Clin Microbiol 2005; 46:
842–849.
0
20
40
60
80
100
0 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16
Amphotericin B concentration (mg/L)
X
T
T
 (%
) a
ct
iv
it
y
0
20
40
60
80
100
0 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16
Voriconazole concentration (mg/L)
X
T
T
 (%
) a
ct
iv
it
y
0
20
40
60
80
100
0 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16
Anidulafungin concentration (mg/L)
X
T
T
 (%
) a
ct
iv
it
y
FIG. 3. In vitro activities of different concentrations of drugs against
bioﬁlms of Candida parapsilosis sensu stricto. The inhibitory effects of
the antifungals were measured as the optical densities of the antifun-
gal-treated wells relative to those of the control (antifungal-free)
wells (considered to be 100%), as determined in the 2,3-bis(2-meth-
oxy-4-nitro-5-sulpho-phenyl)-2H-tetrazolium-5-carboxanilide (XTT)
assays, and are expressed as percentages (MIC50 and MIC80) of the
values for control wells.
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